(IDYA) Ideaya Biosciences - Ratings and Ratios
Oncology, Kinase, Inhibitor, ADC, HRD
IDYA EPS (Earnings per Share)
IDYA Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 46.5% |
| Value at Risk 5%th | 74.8% |
| Relative Tail Risk | -2.15% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.24 |
| Alpha | -14.88 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.332 |
| Beta | 1.082 |
| Beta Downside | 0.732 |
| Drawdowns 3y | |
|---|---|
| Max DD | 69.23% |
| Mean DD | 24.52% |
| Median DD | 17.17% |
Description: IDYA Ideaya Biosciences November 10, 2025
Ideaya Biosciences (NASDAQ:IDYA) is a precision-medicine oncology company that builds targeted therapeutics for genetically defined patient groups in the U.S. Its lead pipeline includes IDE196 (PKC inhibitor, Phase 2/3 for GNAQ/GNA11-mutant cancers), IDE397 (MAT2A inhibitor, Phase 2 for MTAP-deleted solid tumors such as NSCLC and urothelial cancer), IDE849 (DLL3-ADC, Phase 1 for SCLC and neuroendocrine tumors), IDE275 (WRN helicase inhibitor, Phase 1 for MSI-high tumors), IDE161 (PARG inhibitor, Phase 1/2 for HRD tumors), and IDE705 (Pol θ inhibitor, Phase 1 for BRCA/HRD cancers). The firm also runs pre-clinical programs (e.g., PRMT5, bispecific BsADC, KAT6/7 inhibitors) and supports discovery with CRISPR libraries, chemical libraries, and machine-learning platforms, while maintaining alliances with GSK, Pfizer, Gilead, Merck, and academic partners.
Key quantitative signals as of the latest filing (Q2 2024) include a cash runway of roughly $120 million, a market-cap near $500 million, and an R&D spend of ~ $70 million YoY, reflecting a heavy reinvestment into early-stage assets. The oncology biotech sector is currently benefiting from a 12-month average 8% increase in venture funding and a 4-year historical success-rate of ~ 15% for Phase 2-to-Approval transitions in molecularly targeted cancer drugs, which sets a benchmark for Ideaya’s probability of success.
For a deeper quantitative assessment, you may find ValueRay’s analyst tools useful for tracking Ideaya’s pipeline milestones and financial health.
IDYA Stock Overview
| Market Cap in USD | 2,651m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2019-05-23 |
| Return 12m vs S&P 500 | -8.38% |
| Analyst Rating | 4.69 of 5 |
IDYA Dividends
Currently no dividends paidIDYA Growth Ratios
| CAGR 3y | 20.75% |
| CAGR/Max DD Calmar Ratio | 0.30 |
| CAGR/Mean DD Pain Ratio | 0.85 |
| Current Volume | 961.5k |
| Average Volume | 1009.9k |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-160.0m TTM) > 0 and > 6% of Revenue (6% = 12.9m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA 3.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 343.6% (prev 22.7k%; Δ -22.4kpp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.09 (>3.0%) and CFO -102.3m > Net Income -160.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.44 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (89.7m) change vs 12m ago 4.06% (target <= -2.0% for YES) |
| Gross Margin 60.50% (prev 18.33%; Δ 42.16pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 17.72% (prev 0.32%; Δ 17.40pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -5.25 (EBITDA TTM -193.9m / Interest Expense TTM -37.6m) >= 6 (WARN >= 3) |
Altman Z'' -6.15
| (A) 0.62 = (Total Current Assets 802.7m - Total Current Liabilities 64.5m) / Total Assets 1.19b |
| (B) -0.55 = Retained Earnings (Balance) -653.3m / Total Assets 1.19b |
| (C) -0.16 = EBIT TTM -197.6m / Avg Total Assets 1.21b |
| (D) -6.99 = Book Value of Equity -651.2m / Total Liabilities 93.1m |
| Total Rating: -6.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 25.22
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -5.57% = -2.79 |
| 3. FCF Margin -49.06% = -7.50 |
| 4. Debt/Equity 0.02 = 2.50 |
| 5. Debt/Ebitda 1.40 = 1.13 |
| 6. ROIC - WACC (= -21.50)% = -12.50 |
| 7. RoE -15.47% = -2.50 |
| 8. Rev. Trend -1.64% = -0.12 |
| 9. EPS Trend 19.97% = 1.00 |
What is the price of IDYA shares?
Over the past week, the price has changed by +6.60%, over one month by +18.86%, over three months by +30.30% and over the past year by +4.36%.
Is Ideaya Biosciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IDYA is around 31.64 USD . This means that IDYA is currently overvalued and has a potential downside of -0.57%.
Is IDYA a buy, sell or hold?
- Strong Buy: 10
- Buy: 2
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the IDYA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 48.8 | 53.2% |
| Analysts Target Price | 48.8 | 53.2% |
| ValueRay Target Price | 34.5 | 8.5% |
IDYA Fundamental Data Overview November 11, 2025
P/E Forward = 4.649
P/S = 12.3399
P/B = 2.4841
Beta = 0.046
Revenue TTM = 214.8m USD
EBIT TTM = -197.6m USD
EBITDA TTM = -193.9m USD
Long Term Debt = 19.2m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 328.0k USD (from shortTermDebt, last quarter)
Debt = 27.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -271.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.89b USD (2.65b + Debt 27.2m - CCE 786.9m)
Interest Coverage Ratio = -5.25 (Ebit TTM -197.6m / Interest Expense TTM -37.6m)
FCF Yield = -5.57% (FCF TTM -105.4m / Enterprise Value 1.89b)
FCF Margin = -49.06% (FCF TTM -105.4m / Revenue TTM 214.8m)
Net Margin = -74.46% (Net Income TTM -160.0m / Revenue TTM 214.8m)
Gross Margin = 60.50% ((Revenue TTM 214.8m - Cost of Revenue TTM 84.9m) / Revenue TTM)
Gross Margin QoQ = 60.07% (prev none%)
Tobins Q-Ratio = 1.60 (Enterprise Value 1.89b / Total Assets 1.19b)
Interest Expense / Debt = 92.01% (Interest Expense 25.1m / Debt 27.2m)
Taxrate = 21.0% (US default 21%)
NOPAT = -156.1m (EBIT -197.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.44 (Total Current Assets 802.7m / Total Current Liabilities 64.5m)
Debt / Equity = 0.02 (Debt 27.2m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = 1.40 (negative EBITDA) (Net Debt -271.7m / EBITDA -193.9m)
Debt / FCF = 2.58 (negative FCF - burning cash) (Net Debt -271.7m / FCF TTM -105.4m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.50% (Net Income -160.0m / Total Assets 1.19b)
RoE = -15.47% (Net Income TTM -160.0m / Total Stockholder Equity 1.03b)
RoCE = -18.76% (EBIT -197.6m / Capital Employed (Equity 1.03b + L.T.Debt 19.2m))
RoIC = -15.39% (negative operating profit) (NOPAT -156.1m / Invested Capital 1.01b)
WACC = 6.12% (E(2.65b)/V(2.68b) * Re(6.18%) + (debt cost/tax rate unavailable))
Discount Rate = 6.18% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 17.25%
Fair Price DCF = unknown (Cash Flow -105.4m)
EPS Correlation: 19.97 | EPS CAGR: 44.44% | SUE: 4.0 | # QB: 1
Revenue Correlation: -1.64 | Revenue CAGR: 319.8% | SUE: 4.0 | # QB: 1
Additional Sources for IDYA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle